NAA polypeptide-camptothecin conjugate as well as preparation method and application thereof
By coupling with polypeptides and cleavage with Legumain enzyme, the problem of poor water solubility and stability of camptothecin is solved, which significantly improves its inhibitory effect on tumor cells, realizes targeted treatment, reduces side effects, and has a broad range of Application prospects.
Patent Information
- Application Number
- CN202411497247.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-25
- Publication Date
- 2024-12-06
AI Technical Summary
Camptothecin has poor water solubility, poor stability and poor targeting, making it difficult to effectively target tumor cells, resulting in poor efficacy and great side effects when treating tumors.
By coupling with polypeptides, camptothecin is modified with succinic acid and coupling by solid-phase polypeptide synthesis method, NAA polypeptide-camptothecin conjugate is formed, which improves its water solubility and stability, and is cleaved by Legumain enzyme Achieve targeted effects.
It significantly improves the water solubility and stability of camptothecin, enhances its inhibitory effect on cervical cancer, colon cancer and liver cancer cells, reduces the toxic side effects on normal cells, prolongs the blood circulation half-life of the drug, and improves the therapeutic effect. .
Smart Images

Figure CN119080876A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a NAA polypeptide-camptothecin conjugate and a preparation method and application thereof. Background Art
[0002] Camptothecin is an alkaloid first isolated from Camptotheca acuminata by American scientist Monroe E. Wall in 1966. At present, the anti-tumor activity of camptothecin and its derivatives is particularly significant among alkaloids, and has extremely high development prospects. Moreover, as a topoisomerase inhibitor, camptothecin can target the topoisomerase of tumor cells. As one of the important targets of anticancer drugs, topoisomerase is involved in many aspects of DNA metabolism (such as DNA cutting and reconnection) to ensure the various processes of cell division. Interestingly, DNA topoisomerase I is overexpressed in tumor cells, so Topo I is also considered to be one of the most promising targets for anti-tumor drugs. However, camptothecin has the disadvantages of poor water solubility, poor stability, and almost no targeting. Therefore, camptothecin needs to be modified to make it have better therapeutic effects.
[0003] Peptide–drug conjugates (PDCs) are a new drug delivery system that couples drugs through linkers to change the water solubility, lipid solubility, stability, targeting and other characteristics of drugs, thereby improving the therapeutic effect of drugs. Peptides are composed of amino acids, and different peptides can be selected and modified for PDC drugs. Peptides are biodegradable, so immunogenic reactions can be avoided. For example, invention patent CN115737833A discloses a camptothecin polypeptide anti-tumor drug conjugate, which uses cysteine as an intermediate linker, utilizes an amidation reaction to graft cysteine onto 9-aminocamptothecin and a targeted anti-tumor polypeptide, and then oxidizes to form a disulfide bond to couple 9-aminocamptothecin and the targeted anti-tumor polypeptide; it can specifically target and act on tumor sites and tumor cells, so that drug molecules are highly accumulated at the tumor site, has high tumor targeting and retention, realizes targeted precision chemotherapy, and reduces toxic side effects to the body. At the same time, the form of the conjugate effectively improves the stability of 9-aminocamptothecin, prolongs the blood circulation half-life of the drug, and exerts a lasting anti-tumor effect. In the previous research of the inventor, an RGD polypeptide-camptothecin polypeptide drug conjugate (CN111068068A) was obtained, wherein the RGD polypeptide and camptothecin are connected by a succinic acid stem as a connecting arm; the synthesized RGD-camptothecin polypeptide drug conjugate can deliver camptothecin to tumor cells, tissues, tumor microenvironment and other tumor sites to improve the solubility of camptothecin, and make the drug camptothecin have a targeted effect, reduce the toxic side effects on normal cells and tissues, and thus achieve the purpose of specific anti-tumor. In addition, the problem of difficulty in modifying the 20-OH of camptothecin and low reaction efficiency was overcome in this study.
[0004] On the basis of the previous research, the inventors conducted continuous research and continued to modify the peptide at the 20-OH of camptothecin, and unexpectedly obtained an NAA peptide-camptothecin conjugate, which has significant effects in treating cervical cancer, colon cancer and liver cancer. At the same time, the peptide NAA, as a linker that can be recognized and cleaved by Legumain, an enzyme highly expressed in the tumor microenvironment, can be coupled with peptides, antibodies, proteins, PEG, fatty acids, etc. on the basis of NAA peptide-camptothecin, thereby achieving the effect of targeting or extending the half-life, and has broad application prospects. Summary of the invention
[0005] The primary purpose of the present invention is to provide a targeted NAA polypeptide-camptothecin conjugate, the structural formula of the NAA polypeptide-camptothecin conjugate is shown in formula (I):
[0006]
[0007] The second object of the present invention is to provide a method for preparing the NAA polypeptide-camptothecin conjugate, the method comprising the following steps:
[0008] (1) Modification of the 20-OH group of camptothecin by using succinic acid to modify the 20-OH group;
[0009] (2) The peptide is prepared by a solid phase peptide synthesis method; then the modified camptothecin is coupled on the resin; (3) The peptide coupled with camptothecin is cleaved from the resin to obtain a crude product of the targeted peptide-camptothecin conjugate.
[0010] The third object of the present invention is to provide the use of the NAA polypeptide-camptothecin conjugate in the preparation of cancer treatment drugs.
[0011] The fourth object of the present invention is to provide the use of the NAA polypeptide-camptothecin conjugate in the preparation of an agent or drug for inhibiting the growth of cervical cancer cells.
[0012] Preferably, the cervical cancer cells are HeLa cells.
[0013] The fifth object of the present invention is to provide the use of the NAA polypeptide-camptothecin conjugate in the preparation of an agent or drug for inhibiting the growth of colon cancer cells.
[0014] Preferably, the colon cancer cells are HCT-15 cells.
[0015] The sixth object of the present invention is to provide the use of the targeted NAA polypeptide-camptothecin conjugate in the preparation of an agent or drug for inhibiting the growth of liver cancer cells.
[0016] The beneficial effects of the present invention are as follows: the present invention provides an NAA polypeptide-camptothecin conjugate, and the targeted NAA polypeptide-camptothecin conjugate can significantly inhibit the growth of cervical cancer, colon cancer and liver cancer cells, and can be used to prepare drugs for treating cervical cancer, colon cancer and liver cancer. At the same time, the polypeptide NAA, as a linker that can be recognized and cut by Legumain, an enzyme highly expressed in the tumor microenvironment, can be coupled with polypeptides, antibodies, proteins, PEG, fatty acids, etc. on the basis of NAA polypeptide-camptothecin, thereby achieving the effect of targeting or extending the half-life, which is expected to reduce toxic side effects, improve drug efficacy, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Characterization of NAA-targeted peptide-camptothecin conjugate (CPT-AAN-NH2)
[0018] Figure 2 Comparison of water solubility of different targeting peptide-camptothecin conjugates DETAILED DESCRIPTION
[0019] The present invention is further described in detail below in conjunction with the examples, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the technical means used in the following examples and experimental examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used can be obtained from commercial channels. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art.
[0020] In the following examples, the structural formula of CPT-COOH is shown below:
[0021]
[0022] The structural formula of CPT-EWPRPQIPP is shown below:
[0023]
[0024] The structural formula of CPT-AAN is shown below:
[0025]
[0026] Example 1. Preparation of Camptothecin (CPT-COOH)
[0027] Camptothecin and succinic acid were used as raw materials, and dehydrated DCM was used as solvent. DBU was added to react at 0°C. After 4 hours, the reaction was terminated and purified by recrystallization with methanol to obtain the modified product of camptothecin 20-OH, namely CPT-COOH. Example 2: Preparation of a NAA-targeted peptide-camptothecin conjugate
[0028] 1. Preparation method
[0029] (1) Activation of resin
[0030] Weigh 0.2222g of resin and put it in a peptide synthesis tube. Add 6ml of DCM to activate for 30 minutes. After the resin activation is completed, wash it with DCM three times, and use K's test to check whether the amino groups on the resin are intact. If the color of the resin does not change, it means that the amino groups are intact and Fmoc protection can be removed; add 6ml of decapping liquid (100mL of hexahydropyridine is added to 400mL of DMF) to the peptide synthesis tube, react on a 3D shaker for 25 minutes, and wash with DMF, DCM and anhydrous ethanol respectively after the reaction is completed (wash three times each); and use K's test to check whether the decapping is complete. After the Fmoc protection is completely removed, the peptide synthesis reaction can be carried out;
[0031] (2) Synthesis of NAA
[0032] Asn-Ala-Ala was reacted with the resin in sequence to obtain NAA peptide resin; the peptide solid phase synthesis method was used to feed in the order of Asn, Ala, and Ala, and Fmoc was removed twice using a commercially available 20% piperidine / DMF solution (100 ml / 400 ml), and nitrogen was blown at room temperature for 10 min and 5 min respectively. After the reaction, it was washed with DMF 6 times, and commercially available ninhydrin:phenol:piperidin (2:1:1) was used for detection for 30-60 s. If the resin turned dark blue, it proved that Fmoc was successfully removed;
[0033] (3) Camptothecin conjugation
[0034] Weigh 60 mg of CPT-COOH, 1.09 g of EDC.Cl, 0.956 g of HBTU and 40 mg of DMAP and dissolve them in 10 ml of DMF. Add the dissolved mixture to the peptide synthesis tube of the above reaction and place it on a 3D shaker to react with the peptide resin for 120 minutes. After the reaction is completed, use K test to detect whether the reaction is complete, and continue to repeat the above washing, deprotection of Fmoc and detection steps.
[0035] (4) Product cleavage
[0036] 8 ml of cleavage solution (prepared by adding 0.4 ml of TIS and 0.4 ml of H2O to 7.6 ml of trifluoroacetic acid) was added to the peptide synthesis tube of the above reaction and reacted on a 3D shaker for 4 hours to cleave the product from the resin.
[0037] (5) Extraction of crude product
[0038] The reaction solution after cleavage was then added to 30 ml of cold ether and placed in a refrigerator to stand for 3 hours to precipitate a yellow-green precipitate. The yellow-green precipitate was centrifuged to obtain a crude product of CPT-RGD-NH2. The crude product was placed in a refrigerator to freeze solid and then dried with a freeze dryer to obtain a solid product.
[0039] (6) CPT-AAN-Purification
[0040] The obtained crude product was purified using a SB-C18 column on a high performance liquid chromatograph, the separated acetonitrile and water mixture was placed in a refrigerator for freezing, and then the yellow powder obtained by drying with a freeze dryer was the target product CPT-AAN.
[0041] 2. Characterization of CPT-AAN
[0042] The compounds were detected and analyzed using LC-MS. Figure 1As shown, it can be seen that the obtained MS product peak is consistent with the target product peak, the target product can be obtained, and subsequent experiments can be carried out.
[0043] Example 2: Water solubility of NAA-targeted polypeptide-camptothecin conjugates
[0044] 1. Experimental Methods
[0045] Camptothecin is an alkaloid that is insoluble in water and is also difficult to dissolve in most organic solvents. This is one of the important factors that make camptothecin difficult to make into a drug. Modification of camptothecin with peptides can significantly improve its solubility. Take 0.2 mg of camptothecin and 0.5 mg of CPT-AAN, dissolve them in 1 ml of ultrafiltered water respectively, and observe their dissolution.
[0046] 2. Experimental results
[0047] The experimental results are as follows Figure 2 As shown in Table 1, the camptothecin solution is a light yellow turbid solution, while the CPT-AAN solution is a light yellow clear solution. The sample dissolved by CPT-AAN is relatively clear, and the solubility is significantly improved compared with CPT.
[0048] Table 1 Water solubility of different targeting peptide-camptothecin conjugates
[0049] sequence Molecular weight Solution properties CPT 348.34 turbid CPT-COOH 448.43 Yellow precipitate CPT-AAN 703.26 Light yellow clear solution CPT-EWPRPQIPP 1547.72 Light yellow clear solution
[0050] Example 3: Study on the effect of targeting NAA polypeptide-camptothecin conjugate in inhibiting cancer cells
[0051] 1. Experimental Methods
[0052] We set up four experimental groups in the experiment, namely:
[0053] CPT group: 1 mg of CPT was weighed and dissolved in 2.8 ml of DMSO to prepare a 1 mM stock solution for later use;
[0054] CPT-COOH group: Weigh 1.5 mg of CPT-COOH and dissolve it in 3.3 ml of DMSO to prepare a 1 mM stock solution for later use;
[0055] CPT-AAN group: Weigh 2 mg of CPT-AAN and dissolve it in 2.8 ml of PBS to prepare a 1 mM stock solution for later use;
[0056] CPT-RGD group: 1.5 mg of CPT-RGD was weighed and dissolved in 1.9 ml of PBS to prepare a 1 mM stock solution for later use;
[0057] CPT-EWPRPQIPP group: Weigh 2 mg of CPT-EWPRPQIPP and dissolve it in 1.3 ml of PBS to prepare a 1 mM stock solution for later use;
[0058] At least 5 replicate wells were set up in each sample. After the cells were cultured for 24 hours, the samples were added in gradient dilutions. The final reaction concentrations were 8, 4, 2, 1, 0.5, 0.25, 0.125, and 0.0625 μM, respectively. The culture was continued for 48 hours. The fixative solution after adding TCA solution for one hour was discarded, and then the plate was washed and dried, and then SRB staining solution was added. After washing and drying the plate, the fuel was dissolved in the solution, and the absorbance was detected at a wavelength of 515 nm to calculate the inhibitory effect of the detected samples on cell growth. Each group of experimental results was repeated 2-3 times, and IC50 was expressed as mean ± variance.
[0059] 2. Experimental results
[0060] The experimental results are shown in Table 2. Compared with the targeted NAA polypeptide-camptothecin conjugate, it has a significant inhibitory effect on HeLa cells (human cervical cancer cells), HCT-15 cells (human colon cancer cells) and SMMC-7721 cells (human liver cancer cells) (all cells were purchased from Wuhan Warner Biotechnology Co., Ltd.).
[0061] Table 2 Inhibitory effects of targeted peptide-camptothecin conjugates on the growth of different cancer cells
[0062]
[0063] Compared with CPT, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
[0064] Compared with CPT, the activity of CPT-AAN at the HeLa and HCT-15 cell levels was basically consistent with that of CPT, with no significant difference. At the SMMC-7721 level, the activity of CPT-AAN was significantly better than that of CPT. CPT-AAN was slightly higher than CPT-RGD at the HeLa, HCT-15 and SMMC-7721 cell levels, and at these three cell levels, the activity of CPT-AAN was significantly higher than that of CPT-COOH and CPT-EWPRPQIPP.
[0065] In summary, the present invention provides a targeted NAA polypeptide-camptothecin conjugate, the water solubility of the targeted NAA polypeptide-camptothecin conjugate is significantly improved, the targeted NAA polypeptide-camptothecin conjugate can significantly inhibit the growth of cervical cancer, colon cancer and liver cancer cells, and can be used to prepare drugs for treating cervical cancer, colon cancer and liver cancer. At the same time, the polypeptide NAA, as a linker that can be recognized and cleaved by Legumain, an enzyme highly expressed in the tumor microenvironment, can be coupled with polypeptides, antibodies, proteins, PEG, fatty acids, etc. on the basis of NAA polypeptide-camptothecin, thereby achieving the effect of targeting or extending the half-life, which is expected to reduce toxic side effects, improve drug efficacy, and has broad application prospects.
Claims
1. A NAA polypeptide-camptothecin conjugate, characterized in that: The structural formula of the NAA polypeptide-camptothecin conjugate is shown in formula (I):
2. The method for preparing the NAA polypeptide-camptothecin conjugate according to claim 1, characterized in that: The preparation method comprises the following steps: (1) Modification of the 20-OH group of camptothecin by using succinic acid to modify the 20-OH group; (2) preparing the polypeptide by solid phase polypeptide synthesis method; and then coupling the modified camptothecin on the resin; (3) The peptide coupled to camptothecin is cleaved from the resin to obtain a crude product of the targeting peptide-camptothecin conjugate.
3. Use of the NAA polypeptide-camptothecin conjugate as claimed in claim 1 in the preparation of drugs for treating cancer.
4. Use of the NAA polypeptide-camptothecin conjugate as claimed in claim 1 in the preparation of an agent or drug for inhibiting the growth of cervical cancer cells.
5. Use of the NAA polypeptide-camptothecin conjugate as claimed in claim 1 in the preparation of an agent or drug for inhibiting the growth of colon cancer cells.
6. Use of the targeted NAA polypeptide-camptothecin conjugate as claimed in claim 1 in the preparation of an agent or drug for inhibiting the growth of liver cancer cells.
